VP, CFO of Protalix BioTherapeutics Inc (PLX, Financial) Yossi Maimon sells 70,000 shares of PLX on 10/07/2010 at an average price of $9.67 a share.
Protalix Biotherapeutics Inc has a market cap of $787 million; its shares were traded at around $9.73 with and P/S ratio of 2071.
PLX is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC, Steven Cohen of SAC Capital Advisors.
Protalix Biotherapeutics Inc has a market cap of $787 million; its shares were traded at around $9.73 with and P/S ratio of 2071.
PLX is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC, Steven Cohen of SAC Capital Advisors.
CFO Recent Trades:
- Sell: VP, CFO Yossi Maimon sold 70,000 shares of PLX stock on 09/07/2010 at the average price of 8.07. The price of the stock has increased by 20.57% since.
Directors and Officers Recent Trades:
- Sell: VP, Product Development Einat Brill Almon sold 70,000 shares of PLX stock on 10/06/2010 at the average price of 9.1. The price of the stock has increased by 6.92% since.
- Sell: VP, Product Development Einat Brill Almon sold 50,000 shares of PLX stock on 09/07/2010 at the average price of 8.07. The price of the stock has increased by 20.57% since.
- Sell: Executive VP, R&D Yoseph Shaaltiel sold 53,027 shares of PLX stock on 08/06/2010 at the average price of 7. Yoseph Shaaltiel owns at least 763,754 shares after this. The price of the stock has increased by 39% since.
- Sell: Executive VP, R&D Yoseph Shaaltiel sold 52,973 shares of PLX stock on 06/21/2010 at the average price of 7. Yoseph Shaaltiel owns at least 816,781 shares after this. The price of the stock has increased by 39% since.
- Sell: Executive VP, R&D Yoseph Shaaltiel sold 12,691 shares of PLX stock on 04/29/2010 at the average price of 7. Yoseph Shaaltiel owns at least 869,754 shares after this. The price of the stock has increased by 39% since.
